Approximately 5% of breast and 15% of ovarian cancer cases were previously thought to arise due to mutations in BRCA1/2; however, HRDetect, a recently proposed weighted model which predicts BRCA1/2 deficiency, has estimated that up to 22% of breast tumors may carry mutations in these genes [8]. This evidence concerns the gene BRCA1 and ovarian cancer.